# Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)

> **NCT00919009** · PHASE2 · COMPLETED · sponsor: **National Cancer Center, Korea** · enrollment: 50 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **PROCEDURE:** TACE (Transcatheter Arterial Chemoembolization )

## Key facts

- **NCT ID:** NCT00919009
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00919009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00919009, "Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00919009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*